Trial · NCT00856050
Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma
NCT00856050, Phase 2, Completed, Dana-Farber Cancer Institute; results first posted 2014-03-19
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma. Trials, record NCT00856050. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00856050
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma
- NCT number
- NCT00856050
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 27 participants, actual
- Lead sponsor
- Dana-Farber Cancer Institute
- Conditions
- Leiomyosarcoma
- Interventions
- letrozole
- First posted
- 2009-03-05
- Last updated
- 2017-04-18
- Results first posted
- 2014-03-19
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression Free Survival Rate at 12 Weeks | 12 weeks | Data below are reported as progression free rate (%). |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Progression Free Survival Rate at 12 Weeks | 12 weeks | 27 patients were enrolled, and 26 patients received at least one dose of study medication and were included in the analysis. | percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression Free Survival Rate at 12 Weeks | Letrozole | 46 | 90% Confidence Interval 29 to 64 | percentage of participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Letrozole | 26 | |
| Overall Study | COMPLETED | Letrozole | 26 | |
| Overall Study | NOT COMPLETED | Letrozole | 0 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhea w/o prior colostomy | Gastrointestinal disorders | Letrozole | 2 | 25 | |
| other | Nausea | Gastrointestinal disorders | Letrozole | 4 | 25 | |
| other | Fatigue | General disorders | Letrozole | 4 | 25 | |
| other | Joint= pain | Musculoskeletal and connective tissue disorders | Letrozole | 5 | 25 | |
| other | Muscle= pain | Musculoskeletal and connective tissue disorders | Letrozole | 7 | 25 | |
| other | Hot flashes | Vascular disorders | Letrozole | 17 | 25 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Letrozole | ||
| Total, other adverse events | Letrozole | 20 | 26 |
| Total, serious adverse events | Letrozole | 0 | 26 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00856050
GET https://conductscience.org/api/trials/v1/NCT00856050/registered